section name header

Pronunciation

val-gan-SYE-kloe-veer audio

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 59.4% absorbed following oral administration, rapidly converted to ganciclovir.

Distribution: Unknown.

Metabolism/Excretion: Rapidly converted to ganciclovir; ganciclovir is mostly excreted by the kidneys.

Half-life: 4.1 hr (intracellular half-life of ganciclovir phosphate is 18 hr).

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: abdominal pain, diarrhea, nausea, vomiting.

GU: fertility, renal impairment.

Hemat: NEUTROPENIA, THROMBOCYTOPENIA, anemia, aplastic anemia, bone marrow depression, pancytopenia.

Neuro: ataxia, paresthesia, peripheral neuropathy , SEIZURES, headache, insomnia, agitation, confusion, dizziness, hallucinations, psychosis, sedation.

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), INFECTION, fever.

Interactions

Drug-Drug:

Drug-Food:

Route/Dosage

Treatment of CMV Disease

Renal Impairment

Renal Impairment

Renal Impairment

Prevention of CMV Disease in Transplant Patients

Renal Impairment

Renal Impairment

Implementation

US Brand Names

Valcyte

Classifications

Therapeutic Classification: antivirals

Availability

(Generic available)

Time/Action Profile

(ganciclovir blood levels)

ROUTEONSETPEAKDURATION
POrapid2 hr12–24 hr

Assessment

Lab Test Considerations:

Patient/Family Teaching

Evaluation/Desired Outcomes

Code

NDC Code*